2015
Profiles of psychiatric disorders among heroin dependent individuals in Changsha, China
Yang M, Liao Y, Wang Q, Chawarski MC, Hao W. Profiles of psychiatric disorders among heroin dependent individuals in Changsha, China. Drug And Alcohol Dependence 2015, 149: 272-279. PMID: 25680517, PMCID: PMC4609506, DOI: 10.1016/j.drugalcdep.2015.01.028.Peer-Reviewed Original ResearchConceptsHeroin-dependent individualsStructured Clinical InterviewMental health disordersSubstance use disordersLow socio-economic statusMood disordersAxis IDSM-IV-TR Axis II Personality DisordersUse disordersClinical InterviewHealth disordersSocio-economic statusDSM-IV-TR Axis IDSM-IV Axis IPersonality disorderDependent individualsAxis II personality disordersLifetime DSM-IV Axis IBorderline personality disorderDrug rehabilitation centersLifetime disordersPatient EditionPsychiatric disordersLifetime diagnosisRehabilitation settings
2013
Impulsivity, cognitive function, and their relationship in heroin-dependent individuals
Zeng H, Lee TM, Waters JH, So KF, Sham PC, Schottenfeld RS, Marienfeld C, Chawarski MC. Impulsivity, cognitive function, and their relationship in heroin-dependent individuals. Journal Of Clinical And Experimental Neuropsychology 2013, 35: 897-905. PMID: 24040894, DOI: 10.1080/13803395.2013.828022.Peer-Reviewed Original ResearchConceptsCognitive functionAbstinent heroin-dependent individualsHeroin-dependent individualsSelf-reported impulsivitySelf-report measuresCognitive abilitiesMotor impulsivityImpulsivityExperience seekingComputerized assessmentMixed evidenceHeroin dependenceIndividualsFunctional weaknessDistractibilityMemorySeekingTherapeutic interventionsInterventionImplicationsMeasuresAbilityRelationshipDecisions
2012
Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia
Ruger JP, Chawarski M, Mazlan M, Ng N, Schottenfeld R. Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia. PLOS ONE 2012, 7: e50673. PMID: 23226534, PMCID: PMC3514172, DOI: 10.1371/journal.pone.0050673.Peer-Reviewed Original ResearchConceptsHeroin dependenceCost-effectiveness ratioSecondary outcomesOutcome measuresDrug usePlacebo-controlled clinical trialFirst heroin useIncremental cost-effectiveness ratioSocietal costsInjection drug useSecondary outcome measuresPrimary outcome measureIllicit opiate useIncremental treatment costNaltrexone treatmentPrimary outcomeMedication costsPlacebo interventionClinical trialsHeroin abstinenceOpiate useHeroin useBuprenorphineTreatment retentionNaltrexone
2011
Costs of Addressing Heroin Addiction in Malaysia and 32 Comparable Countries Worldwide
Ruger JP, Chawarski M, Mazlan M, Luekens C, Ng N, Schottenfeld R. Costs of Addressing Heroin Addiction in Malaysia and 32 Comparable Countries Worldwide. Health Services Research 2011, 47: 865-887. PMID: 22091732, PMCID: PMC3419893, DOI: 10.1111/j.1475-6773.2011.01335.x.Peer-Reviewed Original ResearchConceptsBuprenorphine treatmentOpioid dependence treatmentBlood testingDependence treatmentHeroin addictionHealth systemOpiate usersSimilar interventionsIncremental costLao People's Democratic RepublicPatientsHeroin problemTreatmentGreater percentagePeople's Democratic RepublicInterventionDemocratic RepublicMedicationsBuprenorphineNaltrexoneRCTs
2010
Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: A pilot randomized clinical trial
Chawarski MC, Zhou W, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: A pilot randomized clinical trial. Drug And Alcohol Dependence 2010, 115: 237-239. PMID: 21159452, PMCID: PMC3076517, DOI: 10.1016/j.drugalcdep.2010.09.024.Peer-Reviewed Original ResearchConceptsHIV risk reduction counselingMethadone maintenance treatmentRisk reduction counselingIllicit opiate useHIV risk behaviorsBehavioral drugReduction counselingClinical trialsOpiate useMMT servicesRisk behaviorsPrimary outcome measurePilot clinical trialTime of enrollmentSignificant baseline differencesHeroin-dependent individualsNegative test resultsMMT clinicsDaily medicationMaintenance treatmentMMT programBaseline differencesOutcome measuresMMT groupTreatment retention
2008
Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial
Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. The Lancet 2008, 371: 2192-2200. PMID: 18586174, PMCID: PMC4041792, DOI: 10.1016/s0140-6736(08)60954-x.Peer-Reviewed Original ResearchConceptsFirst heroin useHIV risk behaviorsHeroin dependenceHeroin useHeroin relapseMaintenance treatmentHeroin abstinenceDrug counsellingComputer-generated randomisation sequenceRisk behaviorsEffective public health approachConsecutive daysInterim safety analysisOutpatient research clinicPlacebo-controlled trialEfficacy of naltrexoneHeroin-dependent patientsMonths of enrollmentPrevention of relapseWorldwide health priorityPublic health approachRandomisation sequencePrimary outcomeHIV transmissionHIV riskLong‐Term Treatment with Buprenorphine/Naloxone in Primary Care: Results at 2–5 Years
Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Barry DT, O'Connor PG, Schottenfeld RS. Long‐Term Treatment with Buprenorphine/Naloxone in Primary Care: Results at 2–5 Years. American Journal On Addictions 2008, 17: 116-120. PMID: 18393054, DOI: 10.1080/10550490701860971.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCombined Modality TherapyCounselingCross-Sectional StudiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHeroin DependenceHumansLong-Term CareMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPatient DropoutsPrimary Health CareSubstance Abuse DetectionTreatment OutcomeConceptsOpioid-dependent patientsAdverse eventsSerum transaminasesBuprenorphine/naloxone treatmentSerious adverse eventsBuprenorphine/naloxoneLong-term outcomesOffice-based treatmentIllicit drug useOpioid useClinical stabilityNaloxone treatmentPrimary outcomePatient satisfactionPrimary careTerm treatmentDrug useUrine samplesPatientsTreatmentTransaminaseOutcomesYearsModerate levelsPercent
2007
Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial
Chawarski MC, Mazlan M, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial. Drug And Alcohol Dependence 2007, 94: 281-284. PMID: 18164145, DOI: 10.1016/j.drugalcdep.2007.11.008.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance treatmentOpioid-negative urine testsHIV risk reduction counselingRisk reduction counselingHIV risk behaviorsBehavioral drugReduction counselingUrine testsClinical trialsDrug counselingRisk behaviorsSelf-reported HIV risk behaviorsTake-home dosesUrine toxicology testsHeroin-dependent individualsIndividual drug counselingSelf-reported drug useMaintenance treatmentMedication adherenceLimited counselingBuprenorphineDrug useConsecutive abstinenceToxicology testsOverall proportionPrimary Care Office-based Buprenorphine Treatment: Comparison of Heroin and Prescription Opioid Dependent Patients
Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O’Connor P, Schottenfeld RS. Primary Care Office-based Buprenorphine Treatment: Comparison of Heroin and Prescription Opioid Dependent Patients. Journal Of General Internal Medicine 2007, 22: 527-530. PMID: 17372805, PMCID: PMC1829433, DOI: 10.1007/s11606-007-0129-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidBuprenorphineFemaleHeroinHeroin DependenceHumansMaleOffice VisitsOpioid-Related DisordersPrimary Health CareConceptsPrescription opioid useOpioid useOnly patientsPrescription opioidsTreatment outcomesBuprenorphine/naloxone maintenanceBuprenorphine/naloxone treatmentOpioid-negative urine samplesPrescription opioid-dependent patientsHepatitis C antibodyDrug treatment historyOpioid-dependent patientsPrimary care officesOffice-based settingClinical characteristicsBuprenorphine treatmentNaloxone treatmentBuprenorphine/Opioid dependenceCare officesDependent patientsTreatment responseC antibodyHeroin usePatients
2006
Heroin dependence and HIV infection in Malaysia
Chawarski MC, Mazlan M, Schottenfeld RS. Heroin dependence and HIV infection in Malaysia. Drug And Alcohol Dependence 2006, 82: s39-s42. PMID: 16769444, DOI: 10.1016/s0376-8716(06)80007-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineDemographyFemaleHeroin DependenceHIV InfectionsHumansMalaysiaMaleNaltrexoneNarcotic AntagonistsPrevalenceRisk-TakingConceptsInjection drug useCurrent injection drug useLifetime injection drug useHIV infectionNeedle sharingHepatitis CHeroin dependenceHigh prevalenceDrug useMajor risk factorChest X-rayHeroin-dependent individualsHIV risk behaviorsHeroin-dependent subjectsConsistent condom useAddiction Severity IndexDrug abuse treatmentRadiological evidenceHepatitis BMean ageRisk factorsClinical trialsMalay ethnicityBaseline assessmentHIV
2002
Treatment of heroin dependence with buprenorphine in primary care
Fiellin DA, Pantalon MV, Pakes JP, O'Connor PG, Chawarski M, Schottenfeld RS. Treatment of heroin dependence with buprenorphine in primary care. The American Journal Of Drug And Alcohol Abuse 2002, 28: 231-241. PMID: 12014814, DOI: 10.1081/ada-120002972.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAmbulatory CareBuprenorphineCombined Modality TherapyConnecticutCounselingDose-Response Relationship, DrugDrug Administration ScheduleFeasibility StudiesFemaleHeroin DependenceHumansMaleMiddle AgedPrimary Health CareSocial SupportTreatment OutcomeUrban PopulationConceptsUrine toxicologyHeroin dependencePrimary careBrief counselingUrine toxicology testsHeroin-dependent patientsPrimary care settingPrimary care centersUrban medical centerBuprenorphine maintenancePrimary outcomeDependent patientsCare centerClinical trialsCare settingsMedical CenterEffective treatmentTreatment retentionBuprenorphinePatientsPotential efficacyToxicology testsMaintenance phaseWeeksCare
2000
Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial
George T, Chawarski M, Pakes J, Carroll K, Kosten T, Schottenfeld R. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biological Psychiatry 2000, 47: 1080-1086. PMID: 10862808, DOI: 10.1016/s0006-3223(99)00310-8.Peer-Reviewed Original ResearchConceptsBuprenorphine-maintained subjectsCocaine dependenceUrine testsBuprenorphine-maintained patientsEffect of disulfiramContinuous cocaine abstinenceCocaine-dependent subjectsDrug use severityBuprenorphine maintenancePlacebo treatmentDisulfiram groupPlaceboCocaine abstinencePotential efficacyDependent subjectsBaseline measuresDisulfiramNumber of daysWeeksHigh rateSubjectsTrialsPreliminary trialTreatmentPreliminary studyThrice-weekly versus daily buprenorphine maintenance
Schottenfeld R, Pakes J, O’Connor P, Chawarski M, Oliveto A, Kosten T. Thrice-weekly versus daily buprenorphine maintenance. Biological Psychiatry 2000, 47: 1072-1079. PMID: 10862807, DOI: 10.1016/s0006-3223(99)00270-x.Peer-Reviewed Original ResearchConceptsSublingual buprenorphineMaintenance treatmentSelf-reported illicit drug useDrug useOpioid agonist maintenance treatmentOpioid-positive urine testsAgonist maintenance treatmentDaily clinic attendanceDaily sublingual buprenorphineThrice-weekly dosingOpioid-dependent patientsUrine toxicology testsSignificant differencesIllicit drug useSelf-reported numberBuprenorphine maintenanceClinic attendanceWeekly doseIllicit opioidsMedication complianceThrice weeklyUrine testsOutcome measuresBuprenorphineCounseling attendance